BioSpace News Archive

Drug Development

Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

Foresee Pharmaceuticals Co., Ltd., announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome.

March 27, 2021
·
3 min read
Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform

Henlius announced the financial results for the year ended 31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation.

March 27, 2021
·
9 min read
FDA

FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma

The U.S. Food and Drug Administration approved Abecma, a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines of therapy.

March 27, 2021
·
5 min read
Policy

Statement from the Chief Public Health Officer of Canada on March 27, 2021

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

March 27, 2021
·
5 min read